Reckitt Benckiser (RB) Monday said, the U.S Food and Drug Administration, or FDA has denied a citizen's petition, regarding a new evaluation of paediatric exposure data, filed by the RB Pharmaceuticals business. The petition recommended FDA to adopt more stringent packaging standards and increased educational interventions to help reduce the number of children exposed to buprenorphine-containing products used to treat opioid dependence.
However, FDA said that existing labelling and safety programmes were sufficient and concluded that the safety data presented by RB Pharmaceuticals did notwarrant these additional measures.
Subsequently, the company has decided to discontinue the sale of its loose tablet bottles of SUBOXONE in the U.S in favour of other effective treatment options that have shown reduced paediatric exposure rates.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.